These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16414250)

  • 41. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
    Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M
    Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies.
    Mintzer JE
    J Clin Psychiatry; 2006; 67 Suppl 10():3-5. PubMed ID: 16965189
    [No Abstract]   [Full Text] [Related]  

  • 43. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
    Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders.
    Simeon J; Milin R; Walker S
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):267-75. PubMed ID: 11817503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
    Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A;
    J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
    Khan BU
    J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670
    [No Abstract]   [Full Text] [Related]  

  • 50. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of risperidone in children with disruptive behavioural disorders.
    Duhig MJ; Saha S; Scott JG
    J Paediatr Child Health; 2013 Jan; 49(1):19-26. PubMed ID: 22050179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
    Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
    Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
    Currier GW; Simpson GM
    J Clin Psychiatry; 2001 Mar; 62(3):153-7. PubMed ID: 11305699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
    Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
    J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
    McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH
    Arch Gen Psychiatry; 1998 Jul; 55(7):633-41. PubMed ID: 9672054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of atypical antipsychotics in elderly patients with dementia.
    Tariot PN; Profenno LA; Ismail MS
    J Clin Psychiatry; 2004; 65 Suppl 11():11-5. PubMed ID: 15264966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liquid risperidone in the treatment of psychotic agitation.
    Tsai C; Puzantian T
    CNS Drugs; 2002; 16(11):777; author reply 778. PubMed ID: 12383033
    [No Abstract]   [Full Text] [Related]  

  • 60. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
    Magalotti SR; Neudecker M; Zaraa SG; McVoy MK
    Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.